Corcept Therapeutics Posts 32% Q2 Revenue Growth Driven by Lifyorli Launch

Key Facts

1Corcept delivered $256.1M in Q2 2026 revenue, representing a 32% year-over-year increase.

2The Lifyorli launch contributed $47.6M to quarterly results while the company maintained profitability.

Reflecting a structural expansion in the endocrine treatment market, Corcept Therapeutics reported robust financial results for the second quarter of 2026. The company delivered $256.1M in revenue, representing a 32% year-over-year increase. According to reports, the launch of Lifyorli contributed $47.6M to the quarterly results, while the firm successfully maintained profitability during this strategic transition phase.

This growth is anchored by Corcept’s evolution into a multi-engine growth platform, supported by clinical studies such as CATALYST and MOMENTUM which suggest a larger addressable market for Cushing’s syndrome than previously estimated. Alongside expansion into oncology, operational data shows the company's ability to offset high expenses with strong top-line growth. Per market data, this performance reflects a stabilizing business model despite the inherent costs of biotech research and development.

Monitoring the stock performance, CORT stood at $111.62 (close September 04, 2026), having traded between a low of $109.26 and a high of $112.13 during that session. Investors should watch for continued momentum in Lifyorli sales and clinical trial updates as key catalysts, amid a broader economic backdrop where the US ISM Manufacturing PMI was recently reported at 54.6 in early September.